CHMP confirms refusal of marketing authorisation for mipomersen (Kynamro®) for familial hypercholesterolaemia

Source: European Medicines Agency Area: News Following a re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the refusal of the marketing authorisation for mipomersen (Kynamro®), intended for the treatment of patients with certain forms of familial hypercholesterolaemia.   At the request of the applicant, the CHMP re-examined its initial negative opinion, and has confirmed the refusal of the marketing authorisation. Please see the link below for details.
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news